GT Biopharma, Inc. (NASDAQ:GTBP) Short Interest Update

GT Biopharma, Inc. (NASDAQ:GTBP) was the recipient of a large growth in short interest in February. As of February 28th, there was short interest totalling 250,300 shares, a growth of 35.8% from the February 13th total of 184,300 shares. Approximately 11.2% of the company’s stock are short sold. Based on an average daily trading volume, of 850,600 shares, the days-to-cover ratio is currently 0.3 days.

GT Biopharma Price Performance

NASDAQ:GTBP traded down $0.04 on Tuesday, hitting $2.37. 21,176 shares of the company’s stock were exchanged, compared to its average volume of 578,983. The firm has a 50-day moving average price of $2.31 and a 200-day moving average price of $2.49. GT Biopharma has a 52 week low of $1.72 and a 52 week high of $10.66. The company has a market cap of $6.00 million, a P/E ratio of -0.34 and a beta of 0.59.

Analyst Ratings Changes

Several equities research analysts have commented on GTBP shares. Roth Capital raised shares of GT Biopharma to a “strong-buy” rating in a research report on Monday, December 2nd. Roth Mkm started coverage on shares of GT Biopharma in a research report on Monday, December 2nd. They set a “buy” rating and a $11.00 price target on the stock.

About GT Biopharma

GT Biopharma, Inc, a clinical stage biopharmaceutical company, focuses on the development and commercialization of immuno-oncology products based on its proprietary Tri-specific Killer Engager (TriKE) fusion protein immune cell engager technology platform. It develops GTB-3550, a single-chain tri-specific recombinant fusion protein conjugate that is in Phase I clinical trial for the treatment of myelodysplastic syndromes, refractory/relapsed acute myeloid leukemia or advanced systemic mastocytosis, and CD33+ malignancies.